FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W123717439> ?p ?o ?g. }

• W123717439 endingPage "784" @default.
• W123717439 startingPage "779" @default.
• W123717439 abstract "The aim of this study was to compare the vessel response between zotarolimus-eluting stents (ZES) and paclitaxel-eluting stents (PES) using intravascular ultrasound.The ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial was a randomized controlled study of zotarolimus-eluting, phosphorylcholine-coated, cobalt-alloy stents for the treatment of de novo coronary lesions compared with using PES for the same treatment.Data were obtained from patients with serial (baseline and 8-months follow-up) intravascular ultrasound analysis available (n = 198). Volumetric analysis was performed for vessel, lumen, plaque, stent, and neointima. Cross-sectional narrowing (given as percentage) was defined as neointimal area divided by stent area. Neointima-free frame ratio was calculated as the number of frames without intravascular ultrasound-detectable neointima divided by the total number of frames within the stent. Subsegment analysis was performed at every matched 1-mm subsegment throughout the stent.At follow-up, the ZES group showed significantly greater percentage of neointimal obstruction (16.6 +/- 12.0% vs. 9.9 +/- 8.9%, p < 0.01) and maximum cross-sectional narrowing (31.8 +/- 16.1% vs. 25.2 +/- 14.9%, p < 0.01) with smaller minimum lumen area than the PES group did. However, the incidence of maximum cross-sectional narrowing >50% was similar in the 2 groups. Neointima-free frame ratio was significantly lower in the ZES group. In overall analysis, whereas the PES group showed positive remodeling during follow-up (13.7 +/- 4.2 mm(3)/mm to 14.3 +/- 4.3 mm(3)/mm), the ZES group showed no significant difference (12.7 +/- 3.6 mm(3)/mm to 12.9 +/- 3.5 mm(3)/mm). In subsegment analysis, significant focal positive vessel remodeling was observed in 5% of ZES and 25% of PES cases (p < 0.05).There were different global and focal vessel responses for ZES and PES. Both drug-eluting stents showed a similar incidence of lesions with severe narrowing despite ZES having a moderate increase in neointimal hyperplasia compared with neointimal hyperplasia in PES. There was a relatively lower neointima-free frame ratio in ZES, suggesting a greater extent of neointimal coverage. (The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions; NCT00217269)." @default.
• W123717439 created "2016-06-24" @default.
• W123717439 creator A5001909899 @default.
• W123717439 creator A5005854434 @default.
• W123717439 creator A5009224311 @default.
• W123717439 creator A5022581615 @default.
• W123717439 creator A5027075532 @default.
• W123717439 creator A5027124029 @default.
• W123717439 creator A5041084808 @default.
• W123717439 creator A5063616074 @default.
• W123717439 creator A5065425489 @default.
• W123717439 creator A5073478428 @default.
• W123717439 creator A5083795861 @default.
• W123717439 creator A5089282109 @default.
• W123717439 date "2009-08-01" @default.
• W123717439 modified "2023-10-09" @default.
• W123717439 title "Intravascular Ultrasound Results From the ENDEAVOR IV Trial" @default.
• W123717439 cites W1437166545 @default.
• W123717439 cites W1527614413 @default.
• W123717439 cites W159452741 @default.
• W123717439 cites W1977893083 @default.
• W123717439 cites W2013275510 @default.
• W123717439 cites W2047334981 @default.
• W123717439 cites W2064290326 @default.
• W123717439 cites W2078761244 @default.
• W123717439 cites W2083630382 @default.
• W123717439 cites W2098255891 @default.
• W123717439 cites W2098457686 @default.
• W123717439 cites W2109197099 @default.
• W123717439 cites W2124439138 @default.
• W123717439 cites W2130250466 @default.
• W123717439 cites W2138306654 @default.
• W123717439 cites W2141684976 @default.
• W123717439 cites W2145784427 @default.
• W123717439 cites W2157880649 @default.
• W123717439 cites W2160533324 @default.
• W123717439 cites W2165483605 @default.
• W123717439 cites W2165806143 @default.
• W123717439 doi "https://doi.org/10.1016/j.jcin.2009.05.015" @default.
• W123717439 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19695548" @default.
• W123717439 hasPublicationYear "2009" @default.
• W123717439 type Work @default.
• W123717439 sameAs 123717439 @default.
• W123717439 citedByCount "43" @default.
• W123717439 countsByYear W1237174392012 @default.
• W123717439 countsByYear W1237174392013 @default.
• W123717439 countsByYear W1237174392014 @default.
• W123717439 countsByYear W1237174392015 @default.
• W123717439 countsByYear W1237174392016 @default.
• W123717439 countsByYear W1237174392017 @default.
• W123717439 countsByYear W1237174392019 @default.
• W123717439 countsByYear W1237174392020 @default.
• W123717439 countsByYear W1237174392021 @default.
• W123717439 countsByYear W1237174392023 @default.
• W123717439 crossrefType "journal-article" @default.
• W123717439 hasAuthorship W123717439A5001909899 @default.
• W123717439 hasAuthorship W123717439A5005854434 @default.
• W123717439 hasAuthorship W123717439A5009224311 @default.
• W123717439 hasAuthorship W123717439A5022581615 @default.
• W123717439 hasAuthorship W123717439A5027075532 @default.
• W123717439 hasAuthorship W123717439A5027124029 @default.
• W123717439 hasAuthorship W123717439A5041084808 @default.
• W123717439 hasAuthorship W123717439A5063616074 @default.
• W123717439 hasAuthorship W123717439A5065425489 @default.
• W123717439 hasAuthorship W123717439A5073478428 @default.
• W123717439 hasAuthorship W123717439A5083795861 @default.
• W123717439 hasAuthorship W123717439A5089282109 @default.
• W123717439 hasConcept C126838900 @default.
• W123717439 hasConcept C131631996 @default.
• W123717439 hasConcept C141071460 @default.
• W123717439 hasConcept C143753070 @default.
• W123717439 hasConcept C2776931568 @default.
• W123717439 hasConcept C2777339539 @default.
• W123717439 hasConcept C2777546689 @default.
• W123717439 hasConcept C2778283817 @default.
• W123717439 hasConcept C2778583881 @default.
• W123717439 hasConcept C2780797203 @default.
• W123717439 hasConcept C2989005 @default.
• W123717439 hasConcept C71924100 @default.
• W123717439 hasConceptScore W123717439C126838900 @default.
• W123717439 hasConceptScore W123717439C131631996 @default.
• W123717439 hasConceptScore W123717439C141071460 @default.
• W123717439 hasConceptScore W123717439C143753070 @default.
• W123717439 hasConceptScore W123717439C2776931568 @default.
• W123717439 hasConceptScore W123717439C2777339539 @default.
• W123717439 hasConceptScore W123717439C2777546689 @default.
• W123717439 hasConceptScore W123717439C2778283817 @default.
• W123717439 hasConceptScore W123717439C2778583881 @default.
• W123717439 hasConceptScore W123717439C2780797203 @default.
• W123717439 hasConceptScore W123717439C2989005 @default.
• W123717439 hasConceptScore W123717439C71924100 @default.
• W123717439 hasIssue "8" @default.
• W123717439 hasLocation W1237174391 @default.
• W123717439 hasLocation W1237174392 @default.
• W123717439 hasOpenAccess W123717439 @default.
• W123717439 hasPrimaryLocation W1237174391 @default.
• W123717439 hasRelatedWork W1826497707 @default.
• W123717439 hasRelatedWork W2036101787 @default.

• next